Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

NASDAQ:AYTU - Nasdaq - US0547548588 - Common Stock - Currency: USD

1.1  -0.01 (-0.9%)

Fundamental Rating

3

AYTU gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. AYTU may be in some trouble as it scores bad on both profitability and health. AYTU is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AYTU has reported negative net income.
In the past year AYTU had a positive cash flow from operations.
In the past 5 years AYTU always reported negative net income.
In the past 5 years AYTU always reported negative operating cash flow.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -4.51%, AYTU is doing good in the industry, outperforming 73.74% of the companies in the same industry.
Looking at the Return On Equity, with a value of -17.04%, AYTU is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROIC N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Gross Margin of AYTU (67.43%) is better than 72.73% of its industry peers.
AYTU's Gross Margin has been stable in the last couple of years.
AYTU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.
AYTU has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AYTU has been increased compared to 5 years ago.
The debt/assets ratio for AYTU is higher compared to a year ago.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

AYTU has an Altman-Z score of -3.32. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
AYTU's Altman-Z score of -3.32 is in line compared to the rest of the industry. AYTU outperforms 43.43% of its industry peers.
The Debt to FCF ratio of AYTU is 29.85, which is on the high side as it means it would take AYTU, 29.85 years of fcf income to pay off all of its debts.
AYTU has a Debt to FCF ratio of 29.85. This is in the better half of the industry: AYTU outperforms 76.26% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that AYTU is not too dependend on debt financing.
AYTU has a Debt to Equity ratio (0.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Altman-Z -3.32
ROIC/WACCN/A
WACC18.92%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.98 indicates that AYTU may have some problems paying its short term obligations.
AYTU has a Current ratio of 0.98. This is amonst the worse of the industry: AYTU underperforms 82.83% of its industry peers.
A Quick Ratio of 0.81 indicates that AYTU may have some problems paying its short term obligations.
With a Quick ratio value of 0.81, AYTU is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.81
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

AYTU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.29%, which is quite impressive.
The Revenue for AYTU has decreased by -30.18% in the past year. This is quite bad
AYTU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 61.82% yearly.
EPS 1Y (TTM)71.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)-30.18%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%-29.27%

3.2 Future

Based on estimates for the next years, AYTU will show a very strong growth in Earnings Per Share. The EPS will grow by 35.64% on average per year.
The Revenue is expected to grow by 9.72% on average over the next years. This is quite good.
EPS Next Y125.68%
EPS Next 2Y57.75%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 0.79, which indicates a rather cheap valuation of AYTU.
Based on the Price/Forward Earnings ratio, AYTU is valued cheaper than 99.49% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, AYTU is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.79
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

AYTU's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AYTU is cheaper than 87.88% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.78
EV/EBITDA -0.73
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AYTU's earnings are expected to grow with 35.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.75%
EPS Next 3Y35.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYTU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (4/28/2025, 2:23:38 PM)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)05-19 2025-05-19
Inst Owners30.53%
Inst Owner Change0.93%
Ins Owners2.35%
Ins Owner Change0.23%
Market Cap6.79M
Analysts82.86
Price Target8.16 (641.82%)
Short Float %1.96%
Short Ratio3.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)117.92%
Min EPS beat(2)8.96%
Max EPS beat(2)226.87%
EPS beat(4)3
Avg EPS beat(4)44.38%
Min EPS beat(4)-78.65%
Max EPS beat(4)226.87%
EPS beat(8)5
Avg EPS beat(8)-428.35%
EPS beat(12)7
Avg EPS beat(12)-308.14%
EPS beat(16)8
Avg EPS beat(16)-261.19%
Revenue beat(2)2
Avg Revenue beat(2)10.13%
Min Revenue beat(2)2.24%
Max Revenue beat(2)18.02%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)18.02%
Revenue beat(8)5
Avg Revenue beat(8)-1.48%
Revenue beat(12)7
Avg Revenue beat(12)-0.12%
Revenue beat(16)8
Avg Revenue beat(16)-1.05%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-189.47%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-21.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.79
P/S 0.1
P/FCF 12.78
P/OCF 10.08
P/B 0.22
P/tB N/A
EV/EBITDA -0.73
EPS(TTM)-1.16
EYN/A
EPS(NY)1.4
Fwd EY127.04%
FCF(TTM)0.09
FCFY7.82%
OCF(TTM)0.11
OCFY9.92%
SpS11.14
BVpS4.99
TBVpS-3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.43%
FCFM 0.77%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Debt/EBITDA 5.94
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 28.57%
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.81
Altman-Z -3.32
F-Score5
WACC18.92%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y125.68%
EPS Next 2Y57.75%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-30.18%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%-29.27%
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year596.71%
EBIT Next 3Y126.9%
EBIT Next 5YN/A
FCF growth 1Y101.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.42%
OCF growth 3YN/A
OCF growth 5YN/A